Shauna Farr-Jones, PhD
Academic Coordinator
Anesthesia
School of Medicine

Education & Training

Show all (2) Hide

• Ph.D. Biochemistry Tufts University 06/1989
• BSc(Hons) Chemistry University of Southampton 6/1980

Grants and Projects

Show all (7) Hide

• Antibody Technology Reseach Center, NIH/NCI, 2014-2019
• Trispecific monoclonal antibody for botulinum neurotoxin intoxication therapy, NIH, 2012-2018
• Broad Spectrum Monoclonal Antibody-based Therapeutic for Botulism, NIH, 2011-2016
• Broad Spectrum Monoclonal Antibody-based Therapeutic for Botulism, NIH, 2011-2015
• Broad Spectrum Monoclonal Antibody-based Therapeutic for Botulism, NIH, 2011-2014
• Trispecific monoclonal antibody for botulinum neurotoxin intoxication therapy, NIH, 2012-2014
• Resource for Biocomputing, Visualization, and Informatics, NIH/NCRR, 1976-2012

Publications (29)

Top publication keywords:
Ultraviolet RaysBotulismSingle-Chain AntibodiesNuclear Magnetic Resonance, BiomolecularAntibody AffinityAntitoxinsDrug Evaluation, PreclinicalBotulinum AntitoxinAntibodies, MonoclonalAntibodies, NeutralizingSerogroupBotulinum ToxinsEpitopesDisinfectionBotulinum Toxins, Type A

• Co-Expression and Co-Purification Enable Manufacturing of a Six-Monoclonal Antibody Botulinum Antitoxin Cocktail.
  Toxins 2026 Davis A, Bajwa K, Martinez Z, Davis RR, Green A, Suber F, Farr-Jones S, Tomic MT
• Single Tri-Epitopic Antibodies (TeAbs) to Botulinum Neurotoxin Serotypes B, E, and F Recapitulate the Full Potency of a Combination of Three Monoclonal Antibodies in Toxin Neutralization.
  Toxins 2025 Lou J, Wen WH, Conrad F, Tam CC, Garcia-Rodriguez C, Farr-Jones S, Marks JD
• Disinfection of needleless connectors for catheters in one second using a hand-held UV device.
  American journal of infection control 2024 Fourkas M, Takami E, Schears GJ, Farr-Jones S, Rasooly J
• A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice.
  Toxins 2023 Fan Y, Lou J, Tam CC, Wen W, Conrad F, Leal da Silva Alves P, Cheng LW, Garcia-Rodriguez C, Farr-Jones S, Marks JD
• Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F.
  PloS one 2022 Fan Y, Sun Z, Conrad F, Wen W, Zhao L, Lou J, Zhou Y, Farr-Jones S, Marks JD

Show all (24 more) Hide

• A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D.
  Toxins 2021 Garcia-Rodriguez C, Yan S, Geren IN, Knopp KA, Dong J, Sun Z, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD
• Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.
  Antibodies (Basel, Switzerland) 2019 Harel ET, Drake PM, Barfield RM, Lui I, Farr-Jones S, Van't Veer L, Gartner ZJ, Green EM, Lourenço AL, Cheng Y, Hann BC, Rabuka D, Craik CS
• Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats.
  Toxins 2019 Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT
• Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model.
  Toxins 2019 Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD
• An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E.
  PloS one 2018 Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT
• Antibody engineering to improve manufacturability.
  Protein expression and purification 2018 Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH
• A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.
  Toxins 2018 Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD
• A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.
  Toxins 2018 Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD
• Discovery of internalizing antibodies to basal breast cancer cells.
  Protein engineering, design & selection : PEDS 2018 Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD
• High-throughput screening: update on practices and success.
  Journal of biomolecular screening 2006 Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R, Biros M
• High-throughput screening: searching for higher productivity.
  Journal of biomolecular screening 2004 Fox S, Farr-Jones S, Sopchak L, Boggs A, Comley J
• High throughput screening 2002: moving toward increased success rates.
  Journal of biomolecular screening 2002 Fox S, Wang H, Sopchak L, Farr-Jones S
• Business and science of proteomics--third annual event. Next-generation technologies for high-throughput proteomics.
  IDrugs : the investigational drugs journal 2001 Farr-Jones S
• The Internet for nuclear magnetic resonance spectroscopists.
  Methods in enzymology 2001 Avizonis D, Farr-Jones S
• Chemokine antagonists as anti-inflammatory and antiviral agents II.
  IDrugs : the investigational drugs journal 2000 Farr-Jones S
• Solution structure of Syrian hamster prion protein rPrP(90-231).
  Biochemistry 1999 Liu H, Farr-Jones S, Ulyanov NB, Llinas M, Marqusee S, Groth D, Cohen FE, Prusiner SB, James TL
• High Throughput Screening for Drug Discovery: Continually Transitioning into New Technology.
  Journal of biomolecular screening 1999 Fox S, Farr-Jones S, Yund MA
• NMR determination of the major solution conformation of a peptoid pentamer with chiral side chains.
  Proceedings of the National Academy of Sciences of the United States of America 1998 Armand P, Kirshenbaum K, Goldsmith RA, Farr-Jones S, Barron AE, Truong KT, Dill KA, Mierke DF, Cohen FE, Zuckermann RN, Bradley EK
• Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform.
  Proceedings of the National Academy of Sciences of the United States of America 1997 James TL, Liu H, Ulyanov NB, Farr-Jones S, Zhang H, Donne DG, Kaneko K, Groth D, Mehlhorn I, Prusiner SB, Cohen FE
• Solution structure of omega-conotoxin MVIIC, a high affinity ligand of P-type calcium channels, using 1H NMR spectroscopy and complete relaxation matrix analysis.
  Journal of molecular biology 1995 Farr-Jones S, Miljanich GP, Nadasdi L, Ramachandran J, Basus VJ
• Converting trypsin to chymotrypsin: ground-state binding does not determine substrate specificity.
  Biochemistry 1994 Hedstrom L, Farr-Jones S, Kettner CA, Rutter WJ
• Crystal versus solution structure of enzymes: NMR spectroscopy of a peptide boronic acid-serine protease complex in the crystalline state.
  Proceedings of the National Academy of Sciences of the United States of America 1989 Farr-Jones S, Smith SO, Kettner CA, Griffin RG, Bachovchin WW
• Crystal versus solution structures of enzymes: NMR spectroscopy of a crystalline serine protease.
  Science (New York, N.Y.) 1989 Smith SO, Farr-Jones S, Griffin RG, Bachovchin WW
• Nitrogen-15 NMR spectroscopy of the catalytic-triad histidine of a serine protease in peptide boronic acid inhibitor complexes.
  Biochemistry 1988 Bachovchin WW, Wong WY, Farr-Jones S, Shenvi AB, Kettner CA